Bayer is pleased to announce today that the U.S. Food and Drug Administration (FDA) has accepted the filing for Bayer’s supplemental Biologics License Application (sBLA) for Betaconnect (proposed name), another delivery option for Betaseron (interferon beta-1b), a treatment for relapsing-remitting multiple sclerosis.“This filing underscores Bayer’s continued, longstanding commitment to meeting the needs of patients taking BETASERON to treat their relapsing forms of MS,” said Dario Mirski, M.D., Vice President and Head, U.S. Medical Affairs, Bayer HealthCare Pharmaceuticals. “We have proudly supported the MS community for more than 20 years.”
Source: Bayer
Filed Under: Drug Discovery
